UTMD UTAH MEDICAL PRODUCTS INC

Overview and Growth

In fiscal 2025, UTAH MEDICAL PRODUCTS INC recorded revenue of $38.52M. Revenue of $38.52M sets the scale for evaluating how effectively sales translated into profit and cash during the year. Compared with $40.90M in fiscal 2024, revenue decreased 5.8%, a top-line contraction that reduced operating scale. Diluted earnings per share were $3.48, translating the period’s attributable earnings into the amount reported for each diluted share. Diluted EPS decreased by 12.1% from $3.96 in fiscal 2024, showing how the earnings change reached shareholders on a per-share basis. The company employed $122.54M of total assets, the balance-sheet base supporting its current operating and cash-flow results. Revenue equaled 0.31x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

Gross profit was $22.00M, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. The gross-profit relationship equaled 57.1% of revenue, quantifying the portion retained before operating expenses were recognized. Operating income was $11.40M, the earnings remaining from reported operations after the company’s recognized operating cost structure. The operating result equaled 29.6% of revenue, placing the absolute operating-income figure in the context of the company’s sales base. EBITDA was $12.23M, adding a pre-interest, tax, depreciation, and amortization view of the company’s earnings capacity. Before income taxes, the company reported $14.11M of earnings, providing a bridge between the operating result and final net income. The pretax margin was 36.6%, relating income before taxes directly to revenue. The reported income-tax provision was $2.82M, the amount recognized between pretax income and the final net-income result. Relative to pretax income, the tax provision measured 20.0%, quantifying the portion of pre-tax earnings paid in income tax.

Liquidity and Capital Structure

At period end, the $122.54M asset base was financed through $3.27M of liabilities and $119.27M of equity. The near-term balance sheet paired $97.74M of current assets with $2.60M of current liabilities at the reporting date. Current assets covered current liabilities by 37.62x, leaving a positive buffer for near-term obligations. Cash and equivalents totaled $85.76M, identifying the most liquid reported component available within the broader current-asset balance. Borrowings totaled $0.00, adding a fixed financing obligation alongside the company’s equity capital. Against book equity, debt measured 0.0x, placing the company’s financial leverage in clear balance-sheet terms. Debt represented 0.0% of total assets, placing borrowing in the context of the company’s full resource base. Equity equaled 97.3% of assets, showing the shareholder-capital layer within the company’s balance sheet. Relative to total assets, liabilities measured 2.7%, complementing the separate equity-based view of the company’s capital structure. The cash-to-assets relationship was 70.0%, comparing reported cash and equivalents with the full positive asset balance. The asset base changed 0.0% from $122.54M in fiscal 2024, leaving current total assets higher year over year. Against $117.43M of equity in fiscal 2024, the current book-equity balance moved 1.6% and ended higher. Compared with $82.98M in fiscal 2024, the current cash balance moved 3.4% and finished higher.

Cash Flow and Earnings Quality

The company reported $14.69M of operating cash flow, a cash inflow that shows the cash generated by operations. Capital spending was $371.00K, absorbing part of the cash generated from operations before free cash flow. Capital expenditures represented 2.5% of operating cash flow, leaving the remainder available as free cash flow. Free cash flow came to $14.32M, leaving a positive amount after capital expenditures. Free cash flow represented 37.2% of revenue, linking post-investment cash generation with the company’s operating scale. The free-cash-flow-to-assets relationship was 11.7%, comparing post-investment cash with the balance-sheet asset base.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.